Mazorelvimab  (Synonyms: SYN023)

Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies^[1][2].

Mazorelvimab (0.01-100 µg/mL) shows cytotoxicity to CVS-11 infected BSR cells with dose-dependent manner, but without effecting on uninfected BSR cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mazorelvimab (0.03-1.0 mg/kg; i.m.; single dose) improves the survival rate of rabies virus (RABV) infected hamsters with dose-dependent manner^[1].
Mazorelvimab (0.003-1 mg/kg; i.m.; single dose) improves the survival rate of RABV infected hamsters with dose-dependent manner. Mazorelvimab (0.003-0.03 mg/kg) has insignificant interference with the serum RVNA level of Syrian hamsters without virus infection^[2].
Mazorelvimab (0.03-1 mg/kg; i.m.; single dose) has protective effect in beagles infected with RABV (BD06)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2419087-89-9

[Mazorelvimab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chao TY, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.  [Content Brief]

  [2]. Chao TY, et al. In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. Trop Med Infect Dis. 2020 Feb 21;5(1):31.  [Content Brief]